How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/nosocomial-pneumonia-due-to-methicillin-sensitive-staphylococcus-aureus.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Nosocomial Pneumonia due to Methicillin-Sensitive Staphylococcus Aureus — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nosocomial Pneumonia due to Methicillin-Sensitive Staphylococcus Aureus (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Nosocomial Pneumonia due to Methicillin-Sensitive Staphylococcus Aureus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2		1996-12-20
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Nosocomial Pneumonia due to Methicillin-Sensitive Staphylococcus Aureus
Assistance Publique - Hôpitaux de Paris · 1 drug in Nosocomial Pneumonia due to Methicillin-Sensitive Staphylococcus Aureus
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Nosocomial Pneumonia due to Methicillin-Sensitive Staphylococcus Aureus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Nosocomial Pneumonia due to Methicillin-Sensitive Staphylococcus Aureus:

Cite this brief

Drug Landscape (2026). Nosocomial Pneumonia due to Methicillin-Sensitive Staphylococcus Aureus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/nosocomial-pneumonia-due-to-methicillin-sensitive-staphylococcus-aureus. Accessed 2026-06-10.

Nosocomial Pneumonia due to Methicillin-Sensitive Staphylococcus Aureus full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing